Abiopharma

News list

Pliant Therapeutics Inc (PLRX)

Event
July 11, 2022, 11:00 UTC

(10% Negative) PLIANT THERAPEUTICS, INC. (PLRX) Announces Delay in placebo Development Timeline Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text

News bot Oct. 2, 2025, 12:24 p.m.

📋 PLIANT THERAPEUTICS, INC. (PLRX) - Clinical Trial Update

Filing Date: 2022-07-11

Accepted: 2022-07-11 07:00:59

Event Type: Clinical Trial Update

Event Details:

Pliant Therapeutics Inc (PLRX) Announces Clinical Trial Update Pliant Therapeutics Inc (PLRX) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: placebo, weeks
Clinical Stage: clinical trial, Clinical Trial
Update Type: Trial Timeline Adjustment
Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
Collaboration: QLF
- targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, Facebook and YouTube. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995
- anticipated in early 2023

🔬 Clinical Development Pipeline (PLIANT THERAPEUTICS, INC.):

Product	Type	Development Stage	Therapeutic Area	Source
Placebo	DRUG	Phase PHASE3	Dermatomyositis	ClinicalTrials.gov
Brepocitinib	DRUG	Phase PHASE3	Dermatomyositis	ClinicalTrials.gov

💼 Business Developments:

Partnership
Acquisition: Not available
Licensing: Not available
Regulatory Approval
Executive Changes: Not available

Structured Data:

Company Name: Pliant Therapeutics Inc
CIK: 0001746473
Ticker Symbol: PLRX
Period End Date: 2022-07-10
Document Type: 8-K